Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.

Gualtieri F, Manetti D, Romanelli MN, Ghelardini C.

Curr Pharm Des. 2002;8(2):125-38. Review.

PMID:
11812254
[PubMed - indexed for MEDLINE]
2.

2-pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs.

Scapecchi S, Martelli C, Ghelardini C, Guandalini L, Martini E, Gualtieri F.

Farmaco. 2003 Sep;58(9):715-22.

PMID:
13679165
[PubMed - indexed for MEDLINE]
3.

Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Malykh AG, Sadaie MR.

Drugs. 2010 Feb 12;70(3):287-312. doi: 10.2165/11319230-000000000-00000. Review.

PMID:
20166767
[PubMed - indexed for MEDLINE]
4.

Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.

Froestl W, Muhs A, Pfeifer A.

J Alzheimers Dis. 2012;32(4):793-887. doi: 10.3233/JAD-2012-121186. Review.

PMID:
22886028
[PubMed - indexed for MEDLINE]
5.

Interaction between psychological and pharmacological treatment in cognitive impairment.

Deberdt W.

Life Sci. 1994;55(25-26):2057-66.

PMID:
7997065
[PubMed - indexed for MEDLINE]
6.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
7.

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.

Froestl W, Muhs A, Pfeifer A.

J Alzheimers Dis. 2013;33(3):547-658. doi: 10.3233/JAD-2012-121537. Review.

PMID:
23042218
[PubMed - indexed for MEDLINE]
8.

Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.

Vernon MW, Sorkin EM.

Drugs Aging. 1991 Jan;1(1):17-35. Review.

PMID:
1794001
[PubMed - indexed for MEDLINE]
9.

4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs.

Manetti D, Martini E, Ghelardini C, Dei S, Galeotti N, Guandalini L, Romanelli MN, Scapecchi S, Teodori E, Bartolini A, Gualtieri F.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2303-6.

PMID:
12824022
[PubMed - indexed for MEDLINE]
10.

Cognition enhancers in age-related cognitive decline.

Riedel WJ, Jolles J.

Drugs Aging. 1996 Apr;8(4):245-74. Review.

PMID:
8920174
[PubMed - indexed for MEDLINE]
11.

Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers.

Martini E, Salvicchi A, Ghelardini C, Manetti D, Dei S, Guandalini L, Martelli C, Melchiorre M, Cellai C, Scapecchi S, Teodori E, Romanelli MN.

Bioorg Med Chem. 2009 Nov 1;17(21):7606-14. doi: 10.1016/j.bmc.2009.08.055. Epub 2009 Sep 3.

PMID:
19786353
[PubMed - indexed for MEDLINE]
12.

Towards better brain management: nootropics.

Malik R, Sangwan A, Saihgal R, Jindal DP, Piplani P.

Curr Med Chem. 2007;14(2):123-31. Review.

PMID:
17266573
[PubMed - indexed for MEDLINE]
13.

Cognition enhancers between treating and doping the mind.

Lanni C, Lenzken SC, Pascale A, Del Vecchio I, Racchi M, Pistoia F, Govoni S.

Pharmacol Res. 2008 Mar;57(3):196-213. doi: 10.1016/j.phrs.2008.02.004. Epub 2008 Feb 15. Review.

PMID:
18353672
[PubMed - indexed for MEDLINE]
14.

Pre-clinical evaluation of cognition enhancing drugs.

Schindler U.

Prog Neuropsychopharmacol Biol Psychiatry. 1989;13 Suppl:S99-115. Review.

PMID:
2694232
[PubMed - indexed for MEDLINE]
15.

[Nootropes (cognition enhancers) and neuroprotectors].

Vornin TA, Seredenin SB.

Eksp Klin Farmakol. 2007 Jul-Aug;70(4):44-58. Review. Russian.

PMID:
18078043
[PubMed - indexed for MEDLINE]
16.

Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.

Froestl W, Pfeifer A, Muhs A.

J Alzheimers Dis. 2013;34(1):1-114. doi: 10.3233/JAD-121729. Review.

PMID:
23186990
[PubMed - indexed for MEDLINE]
17.

Nootropics: preclinical results in the light of clinical effects; comparison with tacrine.

Mondadori C.

Crit Rev Neurobiol. 1996;10(3-4):357-70. Review.

PMID:
8978986
[PubMed - indexed for MEDLINE]
18.

Synthesis of 1-azabicyclo[3.3.0]octane derivatives and their effects as piracetam-like nootropics.

Oka M, Matsumoto Y, Hirooka K, Suzuki T.

Chem Pharm Bull (Tokyo). 2000 Aug;48(8):1121-4.

PMID:
10959574
[PubMed - indexed for MEDLINE]
19.

"Brain-specific" nutrients: a memory cure?

McDaniel MA, Maier SF, Einstein GO.

Nutrition. 2003 Nov-Dec;19(11-12):957-75. Review.

PMID:
14624946
[PubMed - indexed for MEDLINE]
20.

PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics.

Marwaha A, Goel RK, Mahajan MP.

Bioorg Med Chem Lett. 2007 Sep 15;17(18):5251-5. Epub 2007 Jun 30.

PMID:
17643300
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk